Drug intelligence / Profile preview

H15

Development stage: Preclinical

Overview

H15 is a dietary supplement derived from *Boswellia serrata Roxb.*, known for its anti-inflammatory properties. It has demonstrated strong inhibition of pro-inflammatory cytokines in viral-mimicry models, suggesting potential therapeutic applications in conditions such as viral and chronic respiratory inflammation.

Brand names: H15®
Other names: frankincenseBoswellia serrata extractBoswellia carterii extractIndian frankincenseSalai guggul

Targets

ALOX12 (Arachidonate 12-lipoxygenase, 12S type)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on H15.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on H15.

Explore the full profile